How long after taking dydrogesterone tablets will menstruation begin?
Aug 01, 2022
Source: Cainiu Health
Dr. Chen Zhe
Introduction
Typically, patients taking dydrogesterone tablets will experience withdrawal bleeding 3–7 days after discontinuing the medication. Dydrogesterone is a progestogen commonly prescribed for women with irregular menstrual cycles. Most patients require more than 10 days of treatment before a therapeutic effect is observed; thus, withdrawal bleeding usually occurs 3–7 days after stopping the tablets. If a patient’s last menstrual period occurred less than seven days ago, pregnancy should first be ruled out.
Many women have taken dydrogesterone. This medication is indicated for conditions caused by endogenous progesterone deficiency, such as dysmenorrhea—a common gynecological disorder. So, how long after taking dydrogesterone tablets does menstruation begin?
How long after taking dydrogesterone tablets does menstruation begin?
Typically, menstruation occurs 3–7 days after discontinuing dydrogesterone tablets. Dydrogesterone is a progestogen commonly prescribed for patients with irregular menstrual cycles. Most patients require more than 10 days of treatment for the drug to take effect; however, withdrawal bleeding usually occurs within 3–7 days after stopping the tablets. If the patient’s last sexual intercourse occurred less than seven days prior, pregnancy should be ruled out first. If pregnancy is excluded and menstruation still does not occur after an appropriate interval, it is advisable to visit a hospital for a color Doppler ultrasound examination to assess endometrial thickness—often found to be thin (<6 mm) in such cases.
Notably, withdrawal bleeding does not necessarily occur after stopping dydrogesterone tablets; therefore, a definitive diagnosis must be established before initiating therapy. To regulate the menstrual cycle, one capsule is taken twice daily from day 11 through day 25 of the menstrual cycle. Dydrogesterone is also indicated for luteal phase support in patients undergoing ovulation induction or assisted reproductive technology (ART), as well as for fetal protection in pregnant women presenting with threatened miscarriage in early pregnancy or with a history of recurrent miscarriage.
If symptoms suggestive of disease appear, patients should seek timely medical evaluation and actively cooperate with their physicians’ treatment plans. We hope this information has been helpful.
